<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040913</identifier>
<setSpec>0001-6640</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prophylaxis against vertical human immunodeficiency virus with zidovudine and lamivudine and autoimmune neutropenia</dc:title>
<dc:description xml:lang="en">Mother-to-infant transmission is the major means of infection by the human immunodeficiency virus (HIV) in children, Zidovudine (AZT) reduces the risk of vertical transmission, Bone marrow suppression, associated with disorders that include anemia and neutropenia, is the major dose-limiting toxic effect of AZT. On rare occasions, AZT-induced neutropenia in the presence of antineutrophil antibodies has been reported in HIVinfected children, Neutropenia is frequently detected in these patients and can have multiple causes. Antineutrophil antibodies are also prevalent, but their presence does not appear to correlate with the development of neutropenia. There are few studies on the secondary effects of AZT in children exposed during the perinatal period or on the possible consequences of exposure to HIV. We present the case of a newborn who, after treatment to reduce vertical HIV transmission, developed neutropenia in the presence of antineutrophil antibodies. To the best of our knowledge, this rare complication has not been reported previously in a child perinatally exposed to HIV and treated with zidovudine or lamivudine</dc:description>
<dc:creator>Roselló Millet, P</dc:creator>
<dc:creator>Flor Macián, E</dc:creator>
<dc:creator>Paredes Cencillo, C</dc:creator>
<dc:creator>Puig Alcaraz, N</dc:creator>
<dc:creator>Balaguer Martínez, J. V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La transmisión maternofetal es la principal causa de contagio por el virus de la inmunodeficiencia humana (VIH) en niños. La zidovudina (AZT) reduce el riesgo de transmisión vertical. La supresión de la medula ósea, incluyendo anemia y neutropenia, es el mayor efecto tóxico dosisdependiente limitante de la AZT. Excepcionalmente, se ha descrito neutropenia inducida por AZT en presencia de anticuerpos antineutrófilo en niños infectados por el VIH. En niños con infección VIH, se aprecia, con frecuencia, neutropenia como resultado de múltiples causas. La prevalencia de anticuerpos antineutrófilo es frecuente en estos pacientes, pero no parece que exista relación con la evolución a neutropenia. Hay pocos estudios sobre los efectos secundarios de la AZT en niños expuestos desde el periodo perinatal o sobre las posibles consecuencias de la exposición al VIH.    Se presenta el caso de una recién nacida que recibe tratamiento para reducir la transmisión vertical por VIH y desarrolla una neutropenia en presencia de anticuerpos antineutrófilo. Esta rara complicación no ha sido descrita previamente en ningún niño expuesto de forma perinatal al VIH y tratado con zidovudina o lamivudina</dc:description>
<dc:source>Acta Pediatr Esp;63(8): 332-335, sept. 2005. ilus</dc:source>
<dc:identifier>ibc-040913</dc:identifier>
<dc:title xml:lang="es">Profilaxis de la transmisión vertical del VIH con zidovudina y lamivudina y neutropenia autoinmune</dc:title>
<dc:subject>^d9691^s22067</dc:subject>
<dc:subject>^d9691^s22012</dc:subject>
<dc:subject>^d32282^s22054</dc:subject>
<dc:subject>^d23867^s22073</dc:subject>
<dc:subject>^d9691^s22016</dc:subject>
<dc:subject>^d33077^s22073</dc:subject>
<dc:subject>^d5567^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29416^s22038</dc:subject>
<dc:subject>^d32857^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d32857^s22066</dc:subject>
<dc:subject>^d32857^s22045</dc:subject>
<dc:subject>^d22226</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d22402^s22045</dc:subject>
<dc:subject>^d9692^s22053</dc:subject>
<dc:subject>^d9691^s22053</dc:subject>
<dc:subject>^d36615^s22001</dc:subject>
<dc:type>article</dc:type>
<dc:date>200509</dc:date>
</metadata>
</record>
</ibecs-document>
